Black Rock Inc. Rubius Therapeutics, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.14 - $0.31 $54,659 - $121,032	-390,426 Reduced 24.59%	1,197,501 $215,000
Q3 2022 Nov 14, 2022	BUY	$0.46 - $1.29 $74,379 - $208,586	161,695 Added 11.34%	1,587,927 $688,000
Q2 2022 Aug 12, 2022	SELL	$0.79 - $5.98 $1.64 Million - $12.4 Million	-2,080,337 Reduced 59.33%	1,426,232 $1.21 Million
Q1 2022 May 12, 2022	BUY	$4.25 - $10.4 $105,264 - $257,587	24,768 Added 0.71%	3,506,569 $19.3 Million
Q4 2021 Feb 10, 2022	SELL	$9.68 - $17.74 $25,932 - $47,525	-2,679 Reduced 0.08%	3,481,801 $33.7 Million
Q3 2021 Nov 09, 2021	BUY	$17.6 - $25.91 $856,152 - $1.26 Million	48,645 Added 1.42%	3,484,480 $62.3 Million
Q2 2021 Aug 11, 2021	BUY	$22.26 - $28.43 $76.5 Million - $97.7 Million	3,435,835 New	3,435,835 $83.9 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.